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http://dx.doi.org/10.1016/j.ccr.2012.10.003SUMMARYLoss of epithelial organization is a hallmark of carcinomas, but whether polarity regulates tumor growth and
metastasis is poorly understood. To address this issue, we depleted thePar3 polarity gene by RNAi in combi-
nation with oncogenic Notch or Ras61L expression in the murine mammary gland. Par3 silencing dramatically
reduced tumor latency in both models and produced invasive and metastatic tumors that retained epithelial
marker expression. Par3 depletion was associated with induction of MMP9, destruction of the extracellular
matrix, and invasion, all mediated by atypical PKC-dependant JAK/Stat3 activation. Importantly, Par3
expression is significantly reduced in human breast cancers, which correlates with active aPKC and Stat3.
These data identify Par3 as a regulator of signaling pathways relevant to invasive breast cancer.INTRODUCTION
Most solid tumors arise from epithelial cells that have acquired
changes in proliferative and organizational capacity. Epithelial
cells form characteristic intercellular adhesions and possess
apical-basal polarity, which is lost in some invasive and meta-
static cancers in a process related to the epithelial-mesenchymal
transitions (EMTs) that occur during development (Thiery et al.,
2009). However, in many cases, epithelial features are retained.
How epithelial tissues establish their organization in a normal
state and how this organization is disrupted during cancer
progression are still not well understood. In particular, it is largely
unknown if the cell polarity machinery is perturbed during tumor-
igenesis and if such disruptions promote metastasis.
Many of the polarity protein complexes localize to distinct
domains within the plasma membrane. The Par genes (Par1,
Par3, Par4, Par5, Par6, and atypical PKC [aPKC]) encode an
evolutionarily conserved group of polarity proteins that play
key roles in many aspects of cell polarization (Goldstein and
Macara, 2007). To date and to our knowledge, only Par4, a
protein kinase also known as LKB1, has been identified as
a tumor suppressor (Jansen et al., 2009), and it remains uncer-Significance
Although loss of cell polarity is often considered a hallmark of i
role of the polaritymachinery in tumor suppression. Here, we de
lost in human breast cancers. In the context of different oncoge
static colonization of the lungs through the production ofMMP9
the invasive behavior of the tumors. We find that expression o
phospho-Stat3, and MMP9 expression in human breast cance
suppressor.
Cantain if tumorigenesis in patients with mutant LKB1 is caused by
loss of its polarity function.
We have focused on Par3, a multidomain scaffolding protein
required for the spatial organization of several important sig-
naling proteins (Goldstein and Macara, 2007). Par3 is essential
for the delivery of aPKC to the apical surface (Harris and Peifer,
2005; McCaffrey and Macara, 2009), through binding of Par3 to
the adaptor protein Par6, which forms a constitutive complex
with aPKC. Furthermore, aPKC can interact directly with Par3,
which is essential for apical aPKC localization and epithelial
organization (Horikoshi et al., 2009; McCaffrey and Macara,
2009). Loss of aPKC from the apical cortex causes spindle
pole orientation defects and epithelial mis-organization (Hao
et al., 2010). Both the level of aPKC expression and mislo-
calization correlate with increased invasion and metastasis in
breast cancer (Kojima et al., 2008). However, to our knowledge,
whether loss of Par3 has a role in regulating aPKC during tumor-
igenesis is unknown.
Some proteins have oncogenic activity when overexpressed.
The Notch receptor, an important transcriptional regulator of
stem cell fate, is activated by proteolytic cleavage to release
an intracellular domain (NICD), which is found at elevated levelsnvasive cancers, there is little experimental evidence for any
monstrate that Par3 polarity protein expression is frequently
nes, loss of Par3 increases primary tumor growth andmeta-
downstream of Jak/Stat3 signaling, which is responsible for
f Par3 is anticorrelated with phospho-aPKC, phospho-JAK,
rs, establishing Par3 as a potent tumor growth and invasion
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Par3 Is a Tumor Invasion Suppressorin up to 50% of human breast cancers (Pece et al., 2004); and
mammary-specific expression of NICD in mice induces breast
tumors, though with no metastasis (Hu et al., 2006). Additionally,
enhanced growth factor receptor signaling promotes breast
cancer. A central effector of growth factor receptor signaling is
the Ras oncogene, which, although rarely mutated in breast
cancer, is frequently hyperactivated (Clark and Der, 1995).
Elevated expression of Neu/ErbB2 or Met receptors is observed
in 20%–30%and 15%–20%of breast cancers, respectively, and
can inappropriately stimulate Ras-mediated signaling pathways
(Reese and Slamon, 1997; Ponzo and Park, 2010).
Progression of in situ breast carcinomas to metastatic disease
requires additional steps, and it is now established that
inflammation is necessary for this process (Grivennikov and
Karin, 2008). Stat3 has a central role in regulating inflammation
in breast cancer through a cytokine loop involving IL-6 (Grivenni-
kov and Karin, 2008; Schafer and Brugge, 2007). Stat3 is Tyr
phosphorylated by Src or JAK kinases, which induces transloca-
tion to the nucleus. Stat3 can be hyperactivated in breast
cancers, which promotes invasion and metastasis, although
Stat3 activation alone is insufficient to induce tumorigenesis
(Barbieri et al., 2010b; Ranger et al., 2009). Therefore, many of
the processes that drive tumorigenesis andmetastasis are sepa-
rable, but how they relate to tissue organization is not well
understood.
The goal of this study was to determine the role of the apical-
basal cell polarity machinery in tumorigenesis, with a focus on
the Par3 polarity protein. Using a mouse mammary transplant
model coupled with lentiviral transduction, we silenced Par3
expression in the context of two different oncogenes and deter-
mined whether loss of Par3 drives tumor growth and/or metas-
tasis. The expression of Par3 was also examined in human
breast cancers.
RESULTS
Loss of Par3 Cooperates with NICD to Promote
Tumorigenesis
We used lentiviral RNAi to deplete Par3 from primary mammary
epithelial cells (MECs) and transplanted them orthotopically into
the inguinal (#4) mammary fat pads of syngeneic mice. Previ-
ously, we reported that Par3-depletedmammary progenitor cells
form disorganized ductal outgrowths that resemble early ductal
carcinoma in situ (DCIS) (McCaffrey and Macara, 2009). How-
ever, over a period of 24–37 weeks post-transplantation, Par3
depletion did not lead to tumor formation (Figure 1A), suggesting
that Par3 is not a classical tumor suppressor. Next, we asked
whether loss of Par3might enhance tumorigenesis in the context
of an oncogene. We initially used NICD, which is upregulated in
50% of human breast cancers (Pece et al., 2004) and drives
tumor formation in mice after a latency of 9 months (Hu et al.,
2006). Primary MECs isolated from C3H mice were transduced
with lentivirus that expresses active, myc-tagged NICD plus
small hairpin RNAs (shRNAs) to either Luciferase (control) or
murine Par3, using Par3 shRNA that we had validated previously
(McCaffrey andMacara, 2009).We refer to the transducedMECs
as NICD/shLuc and NICD/shPar3, respectively. For each animal,
10,000 NICD/shLuc or NICD/shPar3 MECs were injected into
contralateral inguinal (#4) fat pads of the same mouse. Immuno-602 Cancer Cell 22, 601–614, November 13, 2012 ª2012 Elsevier Incblots of tissue lysates showed that myc-NICD was expressed in
the tumors and that Par3 silencing was efficient (Figure 1B).
Strikingly, loss of Par3 caused a dramatic reduction in tumor
latency for NICD-transduced MECs, with 50% of NICD/shPar3
animals developing tumors by 18 weeks (Figure 1A). We con-
firmed that tumors were derived from cells expressing both
NICD and shPar3 by imaging the GFP marker for the RNAi lenti-
virus and by staining for myc-NICD (Figures 1C and 1D).
We transplanted NICD/shLuc and NICD/shPar3 MECs into
opposite sides of the same mouse, and palpable NICD/shLuc
tumors were rarely formed when mice were sacrificed due to
the NICD/shPar3 tumor burden. However, in some cases, small
NICD/shLuc tumors were found by microscopic examination
of the mammary fat pads (Figure 1D). Consistently, all tumors
were GFP positive, and tumors derived from NICD/shPar3
MECs were much larger than those from the NICD/shLuc
MECs (Figure 1D). Moreover, whereas NICD/shLuc tumors pos-
sessed well-defined boundaries, the loss of Par3 induced a
more invasive phenotype, with cells protruding into the sur-
rounding fat pad (Figure 1E). Both types of tumors retained
epithelial characteristics, including expression of cytokeratin 8,
E-cadherin at intercellular junctions and the tight junction marker
ZO1 at apicolateral boundaries surrounding microlumens
(Figures 1E and 1F). We further examined cellular organization
by staining tumor sections for cytokeratin 8 (K8) and cytokeratin
14 (K14). In normal murine mammary ducts, K14 is expressed
in myoepithelial cells, whereas K8 is restricted to luminal cells
(see Figure S1 available online). Loss of Par3 increased tumor
cell heterogeneity in our NICD model (Figures 1E, 1F, and S1).
NICD/shLuc tumors were homogeneous and predominantly
K8+K14moderate, but the NICD/shPar3 tumors displayed a sub-
stantially greater degree of cellular diversity.
Loss of Par3 Cooperates with Oncogenic H-Ras to
Promote Tumorigenesis
To determine if the promotion of tumor growth by loss of
Par3 is specific to NICD or is of more general importance, we
asked if Par3 depletion cooperates with a different oncogene,
H-Ras61L. Knockdown of Par3 in conjunction with oncogenic
GFP-tagged Ras61L significantly reduced tumor latency com-
pared to GFP-Ras61L alone (Figure 2A). Palpable Ras61L/shPar3
tumors had an average latency of 114 ± 68 days compared to
Ras61L/shLuc, which had a latency of >230 days. By 37 weeks,
92%of Ras61L/shLuc transplant mice remained tumor-free com-
pared to 54% Ras61L/shPar3 transplant mice (Figure 2A). We
confirmed comparable Ras expression levels and efficient Par3
knockdown by immunoblotting tumor lysates (Figure 2B).
Although both Ras61L/shLuc and Ras61L/shPar3 tumors ex-
pressed GFP and were able to grow to comparable sizes (Fig-
ure 2C), Ras61L/shPar3 tumors grew more rapidly and were
consistently more aggressive than Ras61L/shLuc tumors; they
invaded through the peritoneum, with the bulk of the tumors
growing inside the body cavity, and were not detected during
palpation (Figure S2A). Additionally, 30% of the Ras61L/
shPar3 tumors invaded through the skin (data not shown).
Consistent with these differences in invasiveness, Ras61L/shLuc
tumors were more organized and retained regions that pos-
sessed a lobular organization with distinct boundaries, whereas
Ras61L/shPar3 tumors exhibited no discernable organization,.
Figure 1. Loss of Par3 Cooperates with
NICD to Promote Mammary Tumor For-
mation
(A) Kaplan-Meier (KM) curve of tumor-free status in
mice transplanted with shPar3 (n = 17), NICD/
shLuc (n = 11), or NICD/shPar3 (n = 12) MECs.
(B) Tumors arising from orthotopically trans-
planted myc-NICD/shLuc or myc-NICD/shPar3
MECs were immunoblotted for Par3, myc-NICD,
and tubulin.
(C) Immunofluorescence staining of tumor sec-
tions for myc-NICD (red) and GFP (green), which
marks cells expressing shRNA.
(D) Tumors arising from NICD/shLuc or NICD/
shPar3-transduced MECs. GFP is coexpressed
with the shRNA and is used as a marker for
transduction. Arrow indicates small nonpalpable
NICD/shLuc tumors, which were found in 7 of 11
fat pads.
(E) Upper panels show hematoxylin and eosin-
stained (H&E) sections of the edges of NICD/shLuc
and NICD/shPar3 tumors. Lower panels present
tissue sections of the tumor edge stained with CK8
(red) and Hoechst 33258 (DNA, blue). Arrows show
invading cells.
(F) Immunofluorescence staining of tumor sections
for E-cadherin, ZO1, and Hoechst 33342 for DNA.
Scale bars, 50 mm (C), 2 mm (D), 100 mm (E), and
20 mm (F).
See also Figure S1.
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Par3 Is a Tumor Invasion Suppressorand cells appeared more spindle shaped (Figures 2D and 2E). In
contrast, NICD/shPar3 tumors were restricted to the fat pad,
with occasional invasion into the peritoneum.
Ras tumors depleted of Par3 retained expression of ZO1,
which remained localized at sites of cell-cell contacts marking
the boundaries of minilumens (Figure 2D). Unexpectedly, al-
though Ras61L is concentrated at intercellular junctions in the
Ras61L/shLuc tumors, loss of Par3 results in the partial redistri-
bution of the oncoprotein into the cytoplasm (Figure 2D, insets),
which might have consequences for downstream signaling. The
tumors also retained expression of the luminal epithelial marker
K8 (Figure 2E), demonstrating that, as with the NICD model,
the Ras61L tumor cells are disorganized but retain epithelial char-
acteristics in the absence of Par3. The Ras61L/shLuc tumors also
expressed E-cadherin (Figure 2E). In contrast, however, E-cad-
herin (Figure 2E) and b-catenin (Figure S2B) were almost unde-
tectable in Ras61L/shPar3 tumors. The absence of staining
reflects downregulation of expression rather thanmislocalization
(Figures 2F and S2C). Although Ras61L/shPar3 tumor cells wereCancer Cell 22, 601–614, Nmore spindle shaped, there was no
increase in vimentin, a mesenchymal
marker (Figure 2F). Thus, loss of Par3,
specifically in the context of the Ras
oncogene, represses E-cadherin expres-
sion, though not the loss of other luminal
epithelial markers.
Interestingly, Ras61L/shLuc tumor cells
were primarily K8+K14, whereas the
Ras61L/shPar3 tumors were more hetero-
geneous, and included K8+K14 and
K8+K14+ dual-positive cells (Figure 2E). K8+K14+ dual-positive
cells may be undifferentiated progenitors (Raouf et al., 2008;
Shackleton et al., 2006; Villadsen et al., 2007). Together, these
data are consistent with our previous identification of a role for
Par3 in driving progenitor cell differentiation in the mammary
gland (McCaffrey and Macara, 2009). They also indicate that
loss of Par3 causes tissue mis-organization rather than a simple
loss of apical-basal polarity.
Par3 Acts as an Invasion and Metastasis Suppressor
To determine if loss of Par3 promotes metastasis, we examined
the lungs of mice after orthotopic injection of NICD/shLuc or
NICD/shPar3 into mammary fat pads. None of the NICD/shLuc
mice had lung metastases (n = 14), consistent with published
data on NICD transgenic mice (Hu et al., 2006). However,
>80% of NICD/shPar3 mice (n = 17) displayed extensive coloni-
zation, with an average of 32 colonies visible per lung (Figures 3A
and 3B). These values are significantly different (p = 0.0001).
Importantly, lung metastases from both NICD/shPar3 andovember 13, 2012 ª2012 Elsevier Inc. 603
Figure 2. Loss of Par3 Cooperates with Ras61L to Promote Mammary Tumor Formation
(A) KM curve for mice transplanted with MECs expressing GFP/shPar3 (n = 13), Ras61L/shLuc (n = 13), or Ras61L/shPar3 (n = 13).
(B) Immunoblot of primary Ras61L/shLuc and Ras61L/shPar3 tumor lysates.
(C) Micrographs of tumors from transplanted Ras61L/shLuc or Ras61L/shPar3 MECs. GFP indicates tumor cells are transduced with lentivirus.
(D) Immunofluorescence staining of tumor sections for GFP-Ras61L (green) and ZO1 (red).
(E) Immunofluorescence staining of tumor sections for GFP-Ras61L (green) and E-cadherin (red), or CK8 (green) and K14 (red).
(F) Western blot of primary Ras61L/shLuc and Ras61L/shPar3 tumor cell lysates.
Scale bars, 500 mm (C) and 50 mm (D and E).
See also Figure S2.
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Par3 Is a Tumor Invasion SuppressorRas61L/shPar3 tumors were comprised of similar epithelial cell
types as the primary tumors (Figures S3A and S3B). Although
Ras61L alone was sufficient to induce metastasis, loss of Par3
increased the number and size of the colonies (Figure S3C).604 Cancer Cell 22, 601–614, November 13, 2012 ª2012 Elsevier IncAs a further test of metastatic potential, we injected equal
numbers of NICD/shLuc or NICD/shPar3 mammary cells sys-
temically via the tail veins (n = 10), and after 3 weeks, the
lungs were sectioned and examined for metastases. In all cases,.
Figure 3. Suppression of Par3 Increases
Tumor Invasion and Metastasis
(A) Whole-mount GFP fluorescent images of lung
metastases from tumor-bearing mice following
orthotopic mammary gland transplants of MECs
transduced with NICD/shLuc (n = 14) and NICD/
shPar3 (n = 17; p = 0.0001).
(B) Box plots showing the number of metastatic
nodules in lungs from (A).
(C) H&E sections of lungs following tail vein injec-
tions of 3 3 105 MECs transduced with NICD/
shLuc or NICD/shPar3.
(D) Box plots showing the number of metastatic
nodules in lungs (n = 10) following systemic injec-
tions of transduced cells from (C).
(E) Hoechst-stained nuclei of NICD/shLuc or
NICD/shPar3 MECs that invaded through the
Matrigel pad and 8 mm filter inserts after 72 hr.
(F) Quantification of (E); results are average of three
independent experiments. Error bars, 1 SEM.
(G) Same as (E), except invasion through collagen
I gels.
(H) Quantification of (G); results are means of three
independent experiments. Error bars, SEM.
(I) Immunofluorescence staining of NICD/shLuc or
NICD/shPar3 MECs that migrated through the
Matrigel for GFP (green) and ZO1 (red).
Scale bars, 1 cm (A and C), 100 mm (E and G), and
10 mm (I).
See also Figure S3.
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Par3 Is a Tumor Invasion Suppressorcolonization of the lungs was detected (Figure 3C), but metas-
tases produced by NICD/shPar3 cells were significantly larger
and more numerous compared to NICD/shLuc cells (Figure 3D).
These results are consistent with increased efficiency of inva-
sion, dissemination, and colonization and support the hypoth-
esis that Par3 normally can suppress metastatic progression.
To further examine the potential for Par3 to suppress tumor
invasion, we asked if MECs transduced with or without Par3
shRNA and an oncogene would show increased migration
in vitro, using three-dimensional (3D) Matrigel or collagen I inva-
sion assays (Figures 3E–3H, S3D, and S3E). Previously, loss ofCancer Cell 22, 601–614, NPar3 has been reported to inhibit cell
migration in two-dimensional scratch
wound assays (Schmoranzer et al.,
2009). The nontransduced cells showed
no detectable invasion through Matrigel
pads over the time course of the experi-
ment, and silencing of Par3 alone did
not enable invasion (data not shown).
Expression of either the NICD or Ras61L
oncogenes caused a significant number
of cells to penetrate through the Matrigel.
Strikingly, however, the silencing of Par3
in the context of either oncogene caused
a substantial increase in invasion effi-
ciency. Loss of Par3 caused a 3.5-fold
(NICD) and 3.9-fold increase (Ras61L) in
cells that invaded through the 3D matrix,
compared to controls (Figures 3E, 3F,
S3D, and S3E). Invasion of NICD cellsthrough collagen I was also stimulated more than 7-fold by
loss of Par3 (Figures 3G and 3H).
Although most metastatic carcinomas retain epithelial charac-
teristics, it has been proposed that tumor cells might undergo
a transient EMT during dissemination then revert to an epithelial
phenotype when they colonize an ectopic site (Guarino et al.,
2007). We examined the expression of EMT markers in our
cultures and found a modest increase in ZEB1 expression, but
no overall changes in gene expression that would indicate
a complete EMT (Figure S3F). Interestingly, the NICD/shPar3
cells that had migrated through the matrix to the filter retainedovember 13, 2012 ª2012 Elsevier Inc. 605
Figure 4. Loss of Par3 Induces MMP Expression and Cell Detachment in Transformed MECs through Activation of aPKC
(A) RT-PCR on total RNA from tumor tissues expressing either NICD or Ras61L with or without shRNA against Par3, using primers for MMP9 and b-actin (control).
(B) Primary MECs stably expressing NICD/shLuc, NICD/shPar3, Ras61L/shLuc, or Ras61L/shPar3 were plated on fibronectin for 72 hr and imaged by DIC.
Representative images of the various colony phenotypes are shown. Scale bars, 50 mm.
(C) Quantification of cell detachment by MECs expressing NICD/shLuc, NICD/shPar3, and NICD/shPar3 with RNAi-resistant full-length human Par3, or mutant
Par3S827A/S829A that does not bind aPKC.
(D) Immunofluorescent staining of fibronectin under colonies of NICD/shLuc and NICD/shPar3 MECs. Scale bars, 10 mm.
(E) Quantification of cell detachment for NICD/shLuc and NICD/shPar3 MECs with or without 400 pM of MMP inhibitor I.
(F) Quantification of cell detachment for Ras61L/shLuc and Ras61L/shPar3 MECs grown with or without 400 pM MMP9/MMP13 inhibitor I.
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Par3 Is a Tumor Invasion Suppressorexpression of the epithelial marker ZO1 (Figure 3I). We conclude
that in the context of an activated oncogene, loss of Par3 expres-
sion increases invasive behavior, and these cells retain the ability
to express epithelial characteristics.
Loss of Par3 Induces MMP Expression and Cell
Detachment in Transformed Mammary Cells
Migration through 3D matrices often requires expression of
matrix metalloproteinases (MMPs), which degrade the ECM
(Rørth, 2009). To test whether loss of Par3, in the context of an
oncogene, might alter MMP expression, or expression of other
adhesion-related genes, we performed quantitative RT-PCR
array analysis of adhesion-related genes on primary NICD/shLuc
and NICD/shPar3 MECs in vitro, in the absence of selection. In
the context of NICD/shPar3, MMP9 showed the most robust
increase in expression over NICD/shLuc, and MMP9 induction
was second highest in the Ras model, of all genes analyzed
(Tables S1–S4). Changes in MMP9 expression were confirmed
by RT-PCR using different primers (Figure 4A). The expression
of three other genes was upregulated, and ten genes were
reduced in both models (Figure S4A). Expression of other genes
differed between the two models, and the expression of some
other MMPs was reduced (MMP1a, MMP12, and MMP14 for
NICD; and MMP2 and MMP15 for Ras). NICD/shPar3 cells also
showed significant decreases in the protease inhibitors, TIMP1
and TIMP2. Therefore, in both models, metalloproteinase ex-
pression was altered by Par3 depletion, with MMP9 being the
most consistently upregulated gene.
Consistent with induction of MMPs, there was a dramatic
change in colony morphology when Par3 expression was sup-
pressed. Most NICD/shLuc cells grew as monolayers on fibro-
nectin-coated dishes (60%–80%; Figures 4B and 4C). In
contrast, only 10%–30% of NICD/shPar3 cells formed mono-
layers, with the rest detaching as spheroid colonies after several
days’ culture (Figure 4B). Importantly, all cultures adhered nor-
mally during the first 24–48 hr, demonstrating that maintenance
rather than initial adhesive ability of the NICD/shPar3 cells is
defective. Moreover, after trypsinization, detached cells were
able to readhere to new plates, and again the cells began to
detach after 24–48 hr. To determine if loss of Par3 causes defec-
tive attachment to specific types of ECM, we also plated cells on
collagen I. Whereas 67% of NICD/shLuc cells grew as mono-
layer colonies on collagen I, less than 1% of cells lacking Par3
remained as monolayer colonies on collagen I (Figure S4B).
Ras61L-transduced MECs also grew as monolayers, and
silencing of Par3 increased multiple layering, whereas detach-
ment occurred as single cells, rather than as multicellular spher-
oids (Figures 4B, S4C, and S4D). The inability of Ras61L/shPar3
to form spheroids may be due to reduced E-cadherin expression
as noted above, which would prevent cells from maintaining
intercellular adhesions.
Consistent with the idea that ECM degradation is responsible
for cell detachment, staining for fibronectin showed that whereas
the ECMwas intact beneath cells that express NICD alone, it was(G) Quantification of cell detachment for NICD/shLuc and NICD/shPar3 MECs w
(H) Detachment of Ras61L/shLuc and Ras61L/shPar3 MECs grown with or withou
Results are means of at least three independent cultures. Error bars, ±1 SD.
See also Figure S4 and Tables S1–S4.
Canabsent from patches where clusters of detached NICD/shPar3
cells had formed (Figure 4D). Finally, we asked if MMP activity
is required for cell detachment. A MMP inhibitor almost com-
pletely blocked detachment induced by Par3 depletion in the
context of either NICD or Ras (Figures 4E and 4F). To confirm
the involvement of MMP9 in the invasive behavior of the
NICD/shPar3 cells, we used shRNA-lentivirus that target the
murine MMP9 and transduced them together with the NICD
and shPar3 viruses into primary MECs. The two most effective
shRNAs (shMMP9-1 and shMMP9-3) significantly reduced in-
vasion through Matrigel (Figures S4E and S4F). The MMP in-
hibitor also efficiently blocked invasion (Figure S4G). Together,
these data identify a mechanism whereby loss of Par3 induces
MMP9, which triggers degradation of ECM with consequent
cell detachment and increased invasive migration.
Cell Detachment Is Mediated through Inappropriate
Activation of aPKC
To confirm that the adhesion defects were caused by loss of
Par3, we first performed rescue experiments using shRNA-resis-
tant human Par3, which efficiently restored the ability of cells
(85%) to remain attached to the ECM (Figure 4C). Notably,
however, a mutant (Par3S827A/S829A) that is unable to directly
bind and be phosphorylated by aPKC could not rescue the adhe-
sion defects, with only 28% of colonies growing as monolayers
(Figure 4C). Next, to determine more directly whether aPKC
activity is required for adhesion, we plated cells with or without
an aPKC inhibitor. This myristoylated pseudosubstrate peptide
penetrates cell membranes and specifically inhibits aPKC iso-
forms. Inhibition of aPKC completely restored cell-ECM adhe-
sion to NICD/shPar3 and reduced Ras61L/shPar3 multilayering
(Figures 4G and 4H).
Our previous work showed that Par3 is required for normal
localization of aPKC to the apical surface of luminal epithelial
cells (McCaffrey and Macara, 2009). To determine if aPKC is
also mislocalized in NICD/shPar3 cells, we stained for aPKC
and ZO1. In the NICD/shLuc control, ZO1 and aPKC both formed
a tight border around the cells (Figure S4H). Thus, expression of
the NICD oncogene alone is not sufficient to disrupt tight junc-
tions and aPKC localization. In contrast, aPKC was completely
lost from the apical junctions of Par3-depleted NICD MECs.
Cortical ZO1 persisted in Par3-depleted cells but was more
punctate (Figure S4H). This result is consistent with our previous
studies showing that loss of Par3 negatively affects tight junction
formation (Chen and Macara, 2005).
Because inhibiting aPKC can reverse cell detachment, we
asked whether aPKC activity was altered in NICD/shPar3 cells.
Active aPKC is phosphorylated on T403/T410, and immunoblots
of cell lysates for total and p-aPKC revealed a substantial in-
crease in p-aPKCT410 levels in NICD/shPar3 cells (Figure 5A, left
panels). Thus, in these oncogene-transformed mammary cells,
lossofPar3 inducesaPKCactivation.Notably, however, in normal
epithelial cells, although loss of Par3 causes mislocalization of
aPKC, it does not alter T410 phosphorylation (Hao et al., 2010).ith or without 40 mg/ml of aPKC pseudosubstrate inhibitor.
t 40 mg/ml aPKC inhibitor.
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Figure 5. Loss of Par3 Activates Stat3 Signaling through aPKC
(A) Immunoblot of NICD/shLuc and NICD/shPar3 MEC lysates showing active phospho-aPKCT410/403 (pT-aPKC) and total aPKC protein levels with or without
50 nM Stat3 inhibitor, Cucurbitacin I.
(B) Immunofluorescence staining of NICD/shLuc or NICD/shPar3 tumor sections for pStat3Y705 (red) and nuclei (blue). Scale bars, 50 mm.
(C) Quantification of pStat3Y705-positive cells in tumor sections (n = 8).
(D) Immunoblots of lysates from NICD/shLuc or NICD/shPar3 primary MECs. Phospho-antibodies were used to detect pJAKY1007/8 and pStat3Y705.
(E) Immunoblots of NICD/shLuc or NICD/shPar3 MEC lysates with or without 40 mg/ml aPKC inhibitor.
(F) Quantification of cell detachment for NICD/shLuc and NICD/shPar3 MECs grown with or without 50 nM Cucurbitacin I. Results are from two independent
experiments.
(G) Quantification of invasion of NICD/shLuc and NICD/shPar3 MECs through Matrigel with or without 50 nM Cucurbitacin I.
(H) Quantification of invasion of NICD/shLuc, NICD/shPar3, constitutively active Stat3-C, and NICD/shPar3/shStat3 MECs through Matrigel.
(I) Immunoblots of NICD/shLuc or NICD/shPar3 MEC lysates with or without 10 nM JAK inhibitor, Pyridone 6.
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To determine the mechanism by which Par3 controls adhesion
and invasion, we examined potential downstream signaling
pathways. Stat3 activation drives MMP expression in multiple
cancer cells and promotes invasive behavior (Song et al.,
2008; Xie et al., 2004). Active Stat3 is also frequently present at
the invasive edge of tumors (Bromberg andWang, 2009). There-
fore, we stained sections from the NICD tumors for phospho-
Stat3 (pStat3Y705). Although few cells were pStat3Y705 positive
in the NICD/shLuc tumors, silencing Par3 increased the number
of pStat3Y705-positive cells throughout the tumor mass (Figures
5B and 5C).
In many tumors, Stat3 activation can be induced indirectly
through cytokine secretion by infiltrating hematopoietic cells
(Yu et al., 2009). To test whether Stat3 activation is intrinsic to
NICD/shPar3 epithelial cells, we examined transduced, unse-
lected MECs. Only 5% of NICD/shLuc cells expressed detect-
able (but weak) levels of pStat3Y705. Significantly, however,
pStat3Y705 was present in 18% of NICD/shPar3 MECs, with a
higher intensity of staining compared to NICD/shLuc cells (Fig-
ures S5A and S5B). Silencing Par3 in Ras61L MECs also caused
a substantial increase in pStat3Y705, as judged by immunofluo-
rescence (Figures S5C and S5D). We confirmed that loss of
Par3 caused a marked increase in pStat3Y705 levels, as deter-
mined by immunoblot (Figure 5D). Furthermore, conditioned
medium fromNICD/shPar3 cultures failed to induce Stat3 activa-
tion when added to NICD/shLuc cultures (data not shown). We
conclude that Stat3 activation is cell autonomous and does not
depend on paracrine cytokine signaling from immune cells.
To determine whether aPKC acts upstream or downstream of
Stat3 activation, we inhibited Stat3 and examined aPKC activa-
tion by blotting for p-aPKCT403/410. aPKC activity was indepen-
dent of Stat3 activity (Figure 5A). In contrast, treatment of
mammary NICD/shPar3 cells with the aPKCps inhibitor dimin-
ished pStat3Y705 to control levels (Figure 5E), demonstrating
that aPKC acts upstream of Stat3 induction.
Because Stat3 can induce MMP expression in some cancer
cells, we next tested the effect of a selective Stat3 inhibitor,
Cucurbitacin-I (JSI-124), on mammary cell detachment. Cells
were treated with 50 nM Cucurbitacin, 24 hr after being plated
on ECM, and were examined 48 hr later. Cucurbitacin com-
pletely reversed the adhesion defect in NICD/shLuc, NICD/
shPar3, Ras61L/shLuc, and in 80% of Ras61L/shPar3 colonies
(Figures 5F and S5E). Moreover, treatment of NICD/shLuc and
NICD/shPar3 MECs with Cucurbitacin significantly reduced the
invasive potential of the MECs through Matrigel (Figure 5G). In
addition, we asked if reducing Stat3 expression could block
the effects of Par3 depletion in the invasion of MECs through
Matrigel. As shown in Figures 5H and S5F, knockdown of
Stat3 significantly reduced the invasiveness of the oncogene-
transduced cells that lack Par3. These data suggest that activa-
tion of Stat3 is required for the cell detachment and invasive
phenotypes caused by loss of Par3.(J) Quantification of invasion of NICD/shLuc and NICD/shPar3 MECs through Ma
(K) Quantification of lung nodules arising from NICD/shLuc, NICD/shPar3, and
were examined from each lung of five mice for each treatment. Results are mean
SD. ns, not significant.
See also Figure S5.
CanAs a direct test of this hypothesis, we expressed a constitu-
tively active mutant, Stat3-C (Bromberg et al., 1999), in MECs
together with NICD or Ras61L. This mutant phenocopied the
loss of Par3 by reducing cell attachment and increasing invasion
(Figures 5H and S5F). Furthermore, we confirmed that in murine
MECs, active Stat3-C also induces MMP9 (Figure S5G).
Jak phosphorylation was also substantially increased by loss
of Par3 (Figure 5D). To test whether Jak is upstream of Stat3
activation in Par3-depleted cells, we used a specific Jak inhib-
itor, Pyridone 6 (Thompson et al., 2002). This inhibitor blocked
shPar3-dependent Stat3 activation and significantly reduced
invasion of the cells through Matrigel (Figures 5I and 5J).
Importantly, all of the effects on signaling caused by loss of
Par3 in the context of oncogenic activation could be fully
reversed by expression of a GFP fusion of human Par3 (Fig-
ure S5H). GFP-hPar3 did not induce re-expression of the endog-
enous Par3 but inhibited the phosphorylation of aPKC and Stat3
and blocked the induction of MMP9. Therefore, these signaling
responses depend specifically on the loss of Par3 and are not
off-target effects of the shRNA.
Finally, to determine whether the induction of Stat3-mediated
invasive behavior is significant for shPar3-dependent metastasis
in vivo, we measured lung colonization after tail vein injections of
NICD-transformed cells with shRNAs against Par3 alone or Par3
and Stat3. As described above (Figure 3), loss of Par3 caused
a significant increase in lung metastasis, which was completely
suppressed by cosilencing Stat3 (Figure 5K). These data identify
an unanticipated pathway in which loss of Par3 results in the
aPKC-dependent activation of JAK/STAT signaling, which in-
duces MMP9 expression and consequent destruction of the
ECM, increased invasion, and lung metastasis by oncogene-
activated mammary cells.
Par3 Expression Is Frequently Lost in Human Breast
Cancers
To address the relevance of Par3 loss to human breast cancer,
we explored the expression of the PARD3 transcript in tumors
from selected cohorts of patients. Significant reductions in
PARD3 gene expression were apparent in invasive ductal and
lobular carcinomas compared to normal breast tissue (Fig-
ure 6A). Notably, PARD3 expression was also reduced in other
epithelial cancers (Figure S6A).We next analyzed a human tumor
lysate array by immunoblot and found a significant reduction in
PAR3 protein for 50% of the tumors as compared to matched
samples of normal breast tissue from the same patients (Fig-
ure 6Ba). A second, independent matched group of 52 patient
samples also showed significant reduction in PAR3 expression
(Figure 6Bb). The same membranes were also probed for
RanGTPase as a loading control, and the PAR3/RAN ratios
weremeasured, to provide a corrected level of PAR3 (Figure 6C).
To validate the specificity of the Par3 antibody, we probed breast
cancer cell line lysates under similar buffer conditions to those
used in generating the commercial membranes. The antibodytrigel with or without 10 nM Jak inhibitor, Pyridone 6.
NICD/shPar3/shStat3-transformed MECs injected systemically. Five sections
s of at least three independent cultures, unless otherwise noted. Error bars, ±1
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Figure 6. PAR3 Expression Is Reduced in
Human Breast Cancer, Correlating with
Elevated MMP9 Expression
(A) Microarray data showing relative levels of
PARD3 gene expression for invasive ductal carci-
nomas versus matched normal breast tissue from
TCGA (a), Karnoub (b), and Richardson (c) data
sets (see Supplemental Experimental Procedures
for information on data sets).
(B) Human tumor protein array membranes of
mixed carcinomas (a) and ductal carcinomas (b)
with matched normal adjacent tissue were im-
munoblotted for PAR3. IDC, intraductal carci-
noma. TNM classification values are given for each
tumor sample.
(C) Box and whisker plots showing quantification
of band intensities for PAR3 that were normalized
to RAN expression levels in 52 matched human
normal and breast tumor lysates from mixed
carcinomas (a) and ductal carcinomas (b).
(D) Spearman’s correlation coefficients between
PAR3 and MMP9 expression in normal breast,
primary breast tumor, and metastatic human
breast cancers from two independent data sets
(a, accession number GSE1477; b, accession
number GSE7390).
See also Figure S6.
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Par3 Is a Tumor Invasion Suppressorspecifically detected PAR3, with low background and no
nonspecific bands, indicating that the signal detected on the
arrays is PAR3 specific (Figure S6B). In addition, we immuno-
blotted a limited number of freshly isolated normal and breast
tumor samples including three invasive carcinomas (IDC) and
one DCIS, which confirmed a decrease in PAR3 protein expres-
sion in the invasive breast cancer samples compared to normal
tissue (Figure S6C).
To determine if PARD3 expression is associated with any
change in survival probability, we compared Kaplan-Meier plots
for high and low expression of PARD3 using a validated Jetset
probe (Figure S6D). For a set of 2,324patientswith breast cancer,
low PARD3 correlated with a modest but statistically significant
reduction in survival probability (p = 9.8 3 105) (Gyo¨rffy et al.,
2010). Our mouse models had revealed that loss of Par3 trig-
gers the induction of MMP9 and invasion. Therefore, we com-
pared the expression of PARD3 andMMP9 in cohorts of normal
human breast, primary breast cancers, andmetastases. Consis-
tent with a role for loss of PAR3 in regulating metastasis through
MMP9, a significant anticorrelation exists between PARD3 and
MMP9 expression in metastases (Figure 6D). One data set also
showed a significant anticorrelation in primary tumors, although
to a lesser degree than in metastases (Figure 6Db).610 Cancer Cell 22, 601–614, November 13, 2012 ª2012 Elsevier Inc.Par3 protein is localized to tight junc-
tions at the apical/lateral boundary in
murine mammary epithelia (McCaffrey
and Macara, 2009), and immunofluores-
cence of tissue arrays revealed a similar
distribution for human mammary ducts
(Figure 7A, a–c). Strikingly, however,
PAR3 localization was completely lost
in many of the human breast cancersamples (Figure 7A, d–i). From a total of 76 tumor samples exam-
ined, 63 lacked strong cortex-associated PAR3 staining. Impor-
tantly, costaining of tissue sections of 166 human invasive ductal
carcinomas showed that p-aPKC and pSTAT3 were frequently
prominent in regions with weak Par3 staining, whereas regions
with more intense Par3 staining were negative for pSTAT3Y705
and p-aPKC (Figures 7B and 7C). Furthermore, many regions
were dual positive for p-aPKC and pJAK2 (Figure 7D), consistent
with a role for PAR3 in regulating aPKC, JAK, and STAT3 activity
in human breast cancers.
DISCUSSION
The apical-basal polarity of epithelial cells is controlled in part
by the Par proteins together with a group of epithelial-specific
proteins first identified in Drosophila (Crumbs, Scribble [Scrib],
Lgl, Dlg). Loss of such proteins, or their misregulation, might
therefore be expected to play a pivotal role in carcinogenesis,
an idea that has been discussed in numerous reviews (Dow
and Humbert, 2007; Feigin and Muthuswamy, 2009; Januschke
and Gonzalez, 2008; St Johnston and Ahringer, 2010). Yet, there
are surprisingly little published data to support this view. In
Drosophila, Scrib, Lgl, and Dlg can behave as tumor suppressors
Figure 7. PAR3 Protein Expression Is
Reduced and aPKC/STAT3 Signaling Is
Activated in Human Breast Cancers
(A) Tissue sections of human normal and breast
cancers stained for PAR3 (red) and nuclei (blue).
Arrows show PAR3 enriched at the apical mem-
brane. Images represent normal (a–c), infiltrating
ductal carcinoma (d–f), and metastatic carcinoma
(g–i). Scale bars, 100 mm.
(B) Tissue sections of human invasive breast
cancers stained for PAR3 (red) and pSTAT3Y705
(green), representative of 166 stained tumor
samples. Tumors with weak (top, 64% of tumors),
mixed (middle, 28% of tumors), and intense
(bottom, 8% of tumors) PAR3 staining.
(C) Tissue sections of human invasive breast
cancers stained for PAR3 (red) and active phos-
pho-aPKCT560 (green). Arrows show PAR3 en-
riched at apical membrane and weak p-aPKC
staining. Images show representative weak (a,
69% of tumors), mixed (b and c, 25% of tumors),
and intense (d and e, 6% of tumors) p-aPKC
staining.
(D) Tissue sections of human invasive breast
cancers costained for p-aPKCT560 (green) and
pJAK2Y1007/8 (red). Representative images are
shown for five tumor samples (a–e).
(E) Model for cooperative effects of loss of Par3 in
NICD or Ras61L tumors. Loss of Par3 in the context
of either oncogene results in the mislocalization
and inappropriate activation of aPKC, which drives
the induction and activation of Jak/Stat3 signaling,
thereby causing increased MMP expression and
ECM degradation.
Scale bars, 30 mm.
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Par3 Is a Tumor Invasion Suppressor(Bilder et al., 2000; Brumby and Richardson, 2003) and can
cooperate with oncogenes to drive metastasis (Pagliarini and
Xu, 2003; Wu et al., 2010). Deletion of Scrib in prostate epithe-
lium predisposed mice to neoplasia (Pearson et al., 2011).
Silencing of Scrib in murine mammary cells stimulated tumor
growth driven by c-myc but had no effect on tumor latency
and did not induce metastasis (Zhan et al., 2008). Nor does
silencing of Scrib disrupt apical-basal polarity in mammalian
epithelial cells (Dow and Humbert, 2007; Qin et al., 2005). Addi-
tionally, increased aPKC activity or Par6 levels have been linkedCancer Cell 22, 601–614, Nto TGF-b signaling and to breast cancer
invasiveness (Viloria-Petit et al., 2009;
Zhan et al., 2008). However, to date, and
to our knowledge, the only bona fide
tumor suppressor among the polarity
proteins in humans is PAR4/LKB1 (Jan-
sen et al., 2009), and we are not aware
of evidence that other Par proteins func-
tion as invasion suppressors or that
disruption of a polarity gene can induce
tumorigenesis through loss of epithelial
polarity.
To examine this issue, we used lentivi-
ruses to deplete Par3 and express acti-
vated Notch or Ras in primary murine
mammary cells, which were implanted or-thotopically into normal immunocompetent mice. An advantage
of this approach is that multiple changes in gene expression can
be manipulated simultaneously, for instance to couple RNAi with
ectopic expression. Additionally, the same cells can be used
in vitro, without prior selection, to elucidate the molecular mech-
anisms underlying their phenotypes. This cancer model revealed
several unexpected effects of silencing Par3. Most remarkably,
despite the fact that the Ras and NICD oncogenes function
through distinct mechanisms, the phenotypes induced by loss
of Par3 are very similar. Loss of Par3 potently reduced tumorovember 13, 2012 ª2012 Elsevier Inc. 611
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Par3 Is a Tumor Invasion Suppressorlatency in both contexts and increased lung colonization, consis-
tent with in vitro increases in invasiveness and detachment from
the ECM. These effects were independent of any consistent
pattern of EMT. For example, both the NICD and Ras tumors
and metastases retained K8 and ZO1 expression and did not
express the classical mesenchymal markers vimentin or N-cad-
herin, consistent with a classification as luminal-type tumors.
Moreover, loss of Par3 caused the activation of Stat3 and induc-
tion of MMP9 expression in both tumor models. Indeed, the only
consistent difference was that Ras/shPar3 tumors had lost
expression of E-cadherin, whereas cadherin expression was re-
tained in the context of NICD.
What are the underlying mechanisms through which loss of
Par3 triggers rapid tumor growth and invasion? We propose
the following model (Figure 7E). First, Par3 spatially restricts
aPKC at the apical membrane (McCaffrey and Macara, 2009),
and apical localization requires the binding and phosphorylation
of Par3 by aPKC. Notably, overexpression or mislocalization of
aPKC is commonly found in invasive human breast tumors (Ko-
jima et al., 2008; Regala et al., 2005). Loss of Par3 triggers both
the mislocalization and—in the context of at least some onco-
genes—the activation of aPKC, which, unexpectedly, triggers
JAK-dependent activation of Stat3. Stat3 in turn induces MMP
expression, resulting in degradation of the ECM and permitting
escape from the primary tumor. Our results generally agree
with previous data that aPKCswere necessary for STAT3 activity
and MMP1/MMP13 expression in cytokine-stimulated chondro-
cytes (Litherland et al., 2010). However, Litherland et al. (2010)
found a dependence on ERK phosphorylation, whereas we
saw no changes in ERK activation in Par3-depleted cells (data
not shown). Instead, loss of Par3 in an epithelial tumor context
induces Stat3 activation through JAK by a cytokine-independent
mechanism.
Stat3 is normally expressed only at low levels in the devel-
oping mammary gland and is upregulated during involution
to regulate cell death. Nonetheless, active STAT3 is often
found at the invasive edges of tumors (Bromberg and Wang,
2009) and is known to promote metastasis in breast cancer
(Barbieri et al., 2010a). Brugge and colleagues found that
NICD is sufficient to activate STAT3 in MCF10A cells (Mazzone
et al., 2010). However, these cells cannot form normal tight
junctions and do not exhibit cortical polarity (Fogg et al.,
2005). Most likely, therefore, aPKC is not restricted to the api-
cal surface, and NICD expression is sufficient to induce Stat3
activation.
The coupling between polarity proteins, oncogenes, and Stat3
is paralleled to a remarkable degree by Drosophila, in which
clones of epithelial cells lacking the Scrib polarity protein
become highly metastatic in the context of oncogenic Ras
(Pagliarini and Xu, 2003;Wu et al., 2010). Loss of Scrib alone trig-
gers a JNK-dependent apoptotic response through the cell com-
petition pathway, by which neighboring wild-type cells eliminate
the mutant cells; however, the expression of RasV12 switches
this response from apoptosis to uncontrolled proliferation, via
a compensatory mechanism dependent on JAK/STAT activa-
tion. Tantalizingly, loss of a polarity protein in the mammary
gland also stimulates apoptosis, just as inDrosophila (McCaffrey
and Macara, 2009). An important question for the future is
whether this response is mediated by cell competition and612 Cancer Cell 22, 601–614, November 13, 2012 ª2012 Elsevier Incwhether an aberrant compensatory mechanism drives tumor
growth and dissemination when polarity proteins are lost from
oncogene-transformed cells.
The striking effects of Par3 deficiency in the context of
activated oncogenes suggest that polarity proteins might be
suppressors of tumorigenesis in human carcinomas. PAR3 pro-
tein levels are significantly reduced in 50% of breast cancer
samples compared with matched normal tissue, and a large
majority of breast cancers lack normal PAR3 localization.
Importantly, loss of Par3 was tightly correlated with increased
p-aPKC and pSTAT3 across multiple breast tumor samples.
Our data demonstrate that in addition to promoting metastasis
through Stat3/MMPs, reduction of Par3 also reduces tumor
latency, indicating that Par3 may suppress several steps in
tumorigenesis. Microarray data support a broad decrease in
PARD3 gene expression across multiple epithelial cancers,
including invasive ductal carcinoma of the breast. Deletions in
the PARD3 locus have also been identified. For human esoph-
ageal small-cell carcinoma, the PARD3 gene was homozy-
gously deleted in 15%, and expression was reduced in 90%
of cell lines tested, compared to normal esophageal epithelial
cells (Zen et al., 2009). Additionally, small deletions have been
identified within the PARD3 locus in a variety of cancer types
(Rothenberg et al., 2010). Because Par3 functions in a polarity
signaling network, mutations in other components of this net-
work might also contribute to metastasis by human carcinomas.
Together, our data establish that the Par3 polarity protein is
an important suppressor of tumorigenesis and metastasis and
that it may play a significant role in human breast cancer
progression.
EXPERIMENTAL PROCEDURES
Culture Conditions, Antibodies, Immunostaining, and Inhibitors
See Supplemental Experimental Procedures.
Orthotopic Mammary Transplants
All animal procedures were performed in accordance with protocols approved
by the Animal Use Committees at the University of Virginia and McGill
University, Montreal. Freshly isolated mammary cells were transduced with
lentivirus expressing myc-NICD, Ras61L, and control shRNA (shLuc; against
luciferase) or shRNA specific to murine Par3 (shPar3) (Zhang and Macara,
2006). Cells were transduced at an moi of 5 for oncogenes and 10 for shRNA.
For in vivo tumorigenesis, 1 3 104 transduced MECs for NICD experiments or
1 3 105 MECs for Ras61L were injected into cleared fat pads, as described
previously (McCaffrey and Macara, 2009). For assessing tumor incidence
and growth, cells expressing NICD/shLuc were injected in the contralateral
side to NICD/shPar3 of each mouse. Mice were examined biweekly for
palpable tumors. To assess metastasis, cells were transplanted into paired
inguinal (#4) fat pads. Once palpable tumors were found, they were measured
with calipers weekly. Mice were sacrificed when the calculated tumor volume
reached 1 cm3.
Invasion Assays
A total of 2.5 3 104 primary MECs/well was transduced with NICD/shLuc, or
NICD/shPar3, Ras61L/shLuc or Ras61L/shPar3 lentivirus, and 2.5 3 104
Comma-D1 cells/well transduced with Ras61L/shLuc or Ras61L/shPar3 were
plated in 8 mm pore Transwell inserts (Corning) in a 24-well plate format on
top of 100 ml of 50% growth factor-reduced Matrigel or 100 ml of Collagen I
gels (rat tail collagen I; GIBCO), prepared as described by Estecha et al.
(2009). Culture medium was changed twice a day for 3 days. After 72 hr, cells
that had migrated through the Matrigel to the filter were stained with Hoechst
33342 and counted..
Cancer Cell
Par3 Is a Tumor Invasion SuppressorTumor Array
Commercially available membranes (ST2-6X-1 and ST2-6X-2) and SomaPlex
Breast Cancer Tissue Lysate Protein Microarray (PMA2-001-L) from Protein
Biotechnologies were probed according to the manufacturer’s protocol (see
Supplemental Experimental Procedures). Breast tissue was provided by the
University of Virginia Biorepository and Tissue Research Facility. All human
samples were deidentified and are exempt from informed consent.
Statistical Analyses
A Wilcoxon signed-rank test was used to determine the significance (p value)
of tumor-free status in mice for the in vivo tumorigenesis. p Values were deter-
mined using unpaired, two-tailed Student’s t tests for all assays except the
tumor arrays, which used paired two-tailed Student’s t tests.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, four tables, and Supplemental
Experimental Procedures and can be found with this article online at http://dx.
doi.org/10.1016/j.ccr.2012.10.003.
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